454 related articles for article (PubMed ID: 11678474)
1. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
2. Clinical utility of resistance testing.
Stebbing J; Gazzard BG
J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
[No Abstract] [Full Text] [Related]
3. Revisiting the concept of a genetic barrier to resistance.
Rusconi S
J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
[No Abstract] [Full Text] [Related]
4. Interpretation of resistance assay results.
Miller V
Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
[No Abstract] [Full Text] [Related]
5. Reverse transcriptase fidelity and HIV-1 variation.
Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
[No Abstract] [Full Text] [Related]
6. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
7. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
8. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
9. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
10. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
12. Understanding transmitted HIV resistance through the experience in the USA.
Taiwo B
Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
[TBL] [Abstract][Full Text] [Related]
13. Reverse transcriptase fidelity and HIV-1 variation.
Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
[No Abstract] [Full Text] [Related]
14. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
[TBL] [Abstract][Full Text] [Related]
15. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
16. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
Kuritzkes DR
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
[No Abstract] [Full Text] [Related]
17. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
18. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
20. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.
Barth RE; Wensing AM; Tempelman HA; Moraba R; Schuurman R; Hoepelman AI
AIDS; 2008 Oct; 22(16):2210-2. PubMed ID: 18832885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
